Specialized Therapies | HIV and Oncology
Press Releases and Company Announcements
Theratechnologies Named Recipient of the 2021 ADRIQ Innovation Award in the "Life Sciences" Category
Theratechnologies Announces Renewal of Shelf Prospectus and Registration Statement; At-The-Market Facility to be Extended
Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021
Theratechnologies Announces Reimbursement Agreement in Italy for Trogarzo® for Eligible Patients With Multi-Drug Resistant HIV-1
Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies. We currently have a Phase 1 clinical trial underway in oncology using our novel and proprietary SORT1+ Technology™. We also plan to initiate a Phase 3 clinical trial to evaluate tesamorelin as a potential treatment for NASH, a severe liver condition which affects a growing number of people around the world.
Making a difference through innovation
Theratechnologies makes a difference in the lives of patients through the development and commercialization of products addressing important unmet medical needs.